Website beta-cell.com under construction

BETA-CELL is a privately owned biopharmaceutical company that develops novel cell therapy and other products related to Diabetes. The company is a spin-off from the Brussels Free University - Diabetes Research Center (VUB-DRC). The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients. DRC is an internationally recognized center of excellence in the field of diabetes.

BETA-CELL’s technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT® as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC.

Meet us at

29 April, 2010
BioCapital Europe, Amsterdam, Netherlands

3 May, 2010
Bio International Convention, Chicago, USA

11 May, 2010
World Stem Cell & Regenerative Medicine Congress, London, UK

20 May, 2010
Knowledge for Growth, Ghent, Belgium

Contact information

Beta-Cell NV
Laarbeeklaan, 103
B-1090 Brussels (Belgium)

Phone: +32 2 477 43 49
Fax: +32 2 477 43 50
Email: info@beta-cell.com